Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

NCT02447328 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02447328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02447328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
May 29, 2015
Completion date
September 16, 2020
Enrollment
83 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or, metastatic breast cancer